✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Patent 7,964,580 protects EPCLUSA, HARVONI, SOVALDI, and VOSEVI, and is included in seven NDAs.
Protection for EPCLUSA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has seventy-seven patent family members in thirty-four countries.
Summary for Patent: 7,964,580
|Title:||Nucleoside phosphoramidate prodrugs|
|Abstract:||Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: ##STR00001## Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.|
|Inventor(s):||Sofia; Michael Joseph (Doylestown, PA), Du; Jinfa (New Hope, PA), Wang; Peiyuan (Glen Rock, NJ)|
|Assignee:||Pharmasset, Inc. (Princeton, NJ)|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for patent 7,964,580|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Use; Process;|
|Country||Patent Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Argentina||066898||See Plans and Pricing|
|Argentina||110411||See Plans and Pricing|
|Australia||2008232827||See Plans and Pricing|
|Brazil||PI0809654||See Plans and Pricing|
|Brazil||PI0823519||See Plans and Pricing|
|Canada||2682230||See Plans and Pricing|
|>Country||>Patent Number||>Estimated Expiration||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration|